Cargando…

Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018

BACKGROUND: Malaria is the single largest cause of illness in Uganda. Since the year 2008, the Global Fund has rolled out several funding streams for malaria control in Uganda. Among these are mechanisms aimed at increasing the availability and affordability of artemisinin-based combination therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kibira, Denis, Ssebagereka, Anthony, van den Ham, Hendrika A., Opigo, Jimmy, Katamba, Henry, Seru, Morries, Reed, Tim, Leufkens, Hubert G., Mantel-Teeuwisse, Aukje K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944888/
https://www.ncbi.nlm.nih.gov/pubmed/33691704
http://dx.doi.org/10.1186/s12936-021-03680-8
_version_ 1783662764502286336
author Kibira, Denis
Ssebagereka, Anthony
van den Ham, Hendrika A.
Opigo, Jimmy
Katamba, Henry
Seru, Morries
Reed, Tim
Leufkens, Hubert G.
Mantel-Teeuwisse, Aukje K.
author_facet Kibira, Denis
Ssebagereka, Anthony
van den Ham, Hendrika A.
Opigo, Jimmy
Katamba, Henry
Seru, Morries
Reed, Tim
Leufkens, Hubert G.
Mantel-Teeuwisse, Aukje K.
author_sort Kibira, Denis
collection PubMed
description BACKGROUND: Malaria is the single largest cause of illness in Uganda. Since the year 2008, the Global Fund has rolled out several funding streams for malaria control in Uganda. Among these are mechanisms aimed at increasing the availability and affordability of artemisinin-based combination therapy (ACT). This paper examines the availability and affordability of first-line malaria treatment and diagnostics in the private sector, which is the preferred first point of contact for 61% of households in Uganda between 2007 and 2018. METHODS: Cross-sectional surveys were conducted between 2007 and 2018, based on a standardized World Health Organization/Health Action International (WHO/HAI) methodology adapted to assess availability, patient prices, and affordability of ACT medicines in private retail outlets. A minimum of 30 outlets were surveyed per year as prescribed by the standardized methodology co-developed by the WHO and Health Action International. Availability, patient prices, and affordability of malaria rapid diagnostic tests (RDTs) was also tracked from 2012 following the rollout of the test and treat policy in 2010. The median patient prices for the artemisinin-based combinations and RDTs was calculated in US dollars (USD). Affordability was assessed by computing the number of days’ wages the lowest-paid government worker (LPGW) had to pay to purchase a treatment course for acute malaria. RESULTS: Availability of artemether/lumefantrine (A/L), the first-line ACT medicine, increased from 85 to100% in the private sector facilities during the study period. However, there was low availability of diagnostic tests in private sector facilities ranging between 13% (2012) and 37% (2018). There was a large reduction in patient prices for an adult treatment course of A/L from USD 8.8 in 2007 to USD 1.1 in 2018, while the price of diagnostics remained mostly stagnant at USD 0.5. The affordability of ACT medicines and RDTs was below one day’s wages for LPGW. CONCLUSIONS: Availability of ACT medicines in the private sector medicines retail outlets increased to 100% while the availability of diagnostics remained low. Although malaria treatment was affordable, the price of diagnostics remained stagnant and increased the cumulative cost of malaria management. Malaria stakeholders should consolidate the gains made and consider the inclusion of diagnostic kits in the subsidy programme.
format Online
Article
Text
id pubmed-7944888
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79448882021-03-10 Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018 Kibira, Denis Ssebagereka, Anthony van den Ham, Hendrika A. Opigo, Jimmy Katamba, Henry Seru, Morries Reed, Tim Leufkens, Hubert G. Mantel-Teeuwisse, Aukje K. Malar J Research BACKGROUND: Malaria is the single largest cause of illness in Uganda. Since the year 2008, the Global Fund has rolled out several funding streams for malaria control in Uganda. Among these are mechanisms aimed at increasing the availability and affordability of artemisinin-based combination therapy (ACT). This paper examines the availability and affordability of first-line malaria treatment and diagnostics in the private sector, which is the preferred first point of contact for 61% of households in Uganda between 2007 and 2018. METHODS: Cross-sectional surveys were conducted between 2007 and 2018, based on a standardized World Health Organization/Health Action International (WHO/HAI) methodology adapted to assess availability, patient prices, and affordability of ACT medicines in private retail outlets. A minimum of 30 outlets were surveyed per year as prescribed by the standardized methodology co-developed by the WHO and Health Action International. Availability, patient prices, and affordability of malaria rapid diagnostic tests (RDTs) was also tracked from 2012 following the rollout of the test and treat policy in 2010. The median patient prices for the artemisinin-based combinations and RDTs was calculated in US dollars (USD). Affordability was assessed by computing the number of days’ wages the lowest-paid government worker (LPGW) had to pay to purchase a treatment course for acute malaria. RESULTS: Availability of artemether/lumefantrine (A/L), the first-line ACT medicine, increased from 85 to100% in the private sector facilities during the study period. However, there was low availability of diagnostic tests in private sector facilities ranging between 13% (2012) and 37% (2018). There was a large reduction in patient prices for an adult treatment course of A/L from USD 8.8 in 2007 to USD 1.1 in 2018, while the price of diagnostics remained mostly stagnant at USD 0.5. The affordability of ACT medicines and RDTs was below one day’s wages for LPGW. CONCLUSIONS: Availability of ACT medicines in the private sector medicines retail outlets increased to 100% while the availability of diagnostics remained low. Although malaria treatment was affordable, the price of diagnostics remained stagnant and increased the cumulative cost of malaria management. Malaria stakeholders should consolidate the gains made and consider the inclusion of diagnostic kits in the subsidy programme. BioMed Central 2021-03-10 /pmc/articles/PMC7944888/ /pubmed/33691704 http://dx.doi.org/10.1186/s12936-021-03680-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kibira, Denis
Ssebagereka, Anthony
van den Ham, Hendrika A.
Opigo, Jimmy
Katamba, Henry
Seru, Morries
Reed, Tim
Leufkens, Hubert G.
Mantel-Teeuwisse, Aukje K.
Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018
title Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018
title_full Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018
title_fullStr Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018
title_full_unstemmed Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018
title_short Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018
title_sort trends in access to anti‐malarial treatment in the formal private sector in uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944888/
https://www.ncbi.nlm.nih.gov/pubmed/33691704
http://dx.doi.org/10.1186/s12936-021-03680-8
work_keys_str_mv AT kibiradenis trendsinaccesstoantimalarialtreatmentintheformalprivatesectorinugandaanassessmentofavailabilityandaffordabilityoffirstlineantimalarialsanddiagnosticsbetween2007and2018
AT ssebagerekaanthony trendsinaccesstoantimalarialtreatmentintheformalprivatesectorinugandaanassessmentofavailabilityandaffordabilityoffirstlineantimalarialsanddiagnosticsbetween2007and2018
AT vandenhamhendrikaa trendsinaccesstoantimalarialtreatmentintheformalprivatesectorinugandaanassessmentofavailabilityandaffordabilityoffirstlineantimalarialsanddiagnosticsbetween2007and2018
AT opigojimmy trendsinaccesstoantimalarialtreatmentintheformalprivatesectorinugandaanassessmentofavailabilityandaffordabilityoffirstlineantimalarialsanddiagnosticsbetween2007and2018
AT katambahenry trendsinaccesstoantimalarialtreatmentintheformalprivatesectorinugandaanassessmentofavailabilityandaffordabilityoffirstlineantimalarialsanddiagnosticsbetween2007and2018
AT serumorries trendsinaccesstoantimalarialtreatmentintheformalprivatesectorinugandaanassessmentofavailabilityandaffordabilityoffirstlineantimalarialsanddiagnosticsbetween2007and2018
AT reedtim trendsinaccesstoantimalarialtreatmentintheformalprivatesectorinugandaanassessmentofavailabilityandaffordabilityoffirstlineantimalarialsanddiagnosticsbetween2007and2018
AT leufkenshubertg trendsinaccesstoantimalarialtreatmentintheformalprivatesectorinugandaanassessmentofavailabilityandaffordabilityoffirstlineantimalarialsanddiagnosticsbetween2007and2018
AT mantelteeuwisseaukjek trendsinaccesstoantimalarialtreatmentintheformalprivatesectorinugandaanassessmentofavailabilityandaffordabilityoffirstlineantimalarialsanddiagnosticsbetween2007and2018